Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

A contemporary artistic collage depicting a hand holding pills, passing them to another hand. The concept of medication and treatment.

Collaboration

Ionis Sends Polycythemia Vera Drug to Ono in Licensing Deal Worth Nearly $1B Biobucks

Ionis will receive $280 million upfront and could get up to $660 million in future milestone payments. Ono will take charge of late-stage development as well as regulatory and commercialization activities.

March 12, 2025

2 min read

Tristan Manalac

Podcasts

COVID Reflections, Novo’s Next-Gen Weight Loss Struggles, Another Depression Miss, More

BioSpace remembers COVID-19 five years after the pandemic was declared, Novo Nordisk’s CagriSema again misses expectations as the company joins a lawsuit filed by drug compounders against the FDA, Viking secures ample supply of its investigational obesity medication, J&J strikes out in depression, and Makary and Bhattacharya near confirmation.

March 12, 2025

1 min read

Heather McKenzie

Leaders facing business crises, banks drowning due to accidents, financial crises and their consequences, Vector illustration design concept in flat style

Bankruptcy

Bluebird’s Go-Private Deal Highlights Fraught Life Preserver for Struggling Biotechs

Facing declining valuations and funding challenges, public biotechs like bluebird bio are going private to restructure, reduce regulatory burdens and refocus on long-term growth.

March 12, 2025

6 min read

Ana Mulero

Lawyers legal office law statue representing blind justice courts figure with scales and sword

Bankruptcy

16 Years And 3 Texas Two-Steps Later, J&J’s Talc Lawsuit Awaits Key Ruling

Johnson & Johnson has been fighting thousands of lawsuits over its now-discontinued talc products for 16 years. A pending judge’s ruling could finally put the issue to bed once and for all.

March 12, 2025

4 min read

Annalee Armstrong

Hands in black and white dropping a collection of pills on a pink background

Manufacturing

Viking Secures 1B Supply of Obesity Pill Candidate With $150M Prepayment Deal

Analysts acknowledged the long-term manufacturing deal could dull Viking’s takeout prospects but hailed it as a smart move to ensure supply.

March 11, 2025

2 min read

Annalee Armstrong

Pictured: Entrance to Pfizer's office in Belgium

Breast cancer

Pfizer, Arvinas Post Mixed Late-Stage Breast Cancer Data for Closely Watched PROTAC Drug

Vepdegestrant did not improve progression-free survival broadly but saw improvements in one specific patient cohort. Arvinas’ stock took a 43% tumble on the news, and analysts are downcast on the drug’s prospects.

March 11, 2025

2 min read

Tristan Manalac

Man with medical or hygienic mask standing over dead covid 19 or Corona virus raised their hand to win the Covic-19 or Coronavirus, At last mankind will win and survive over the virus concept

Editorial

The Shape of a Pandemic: Boom, Bust and Recover

As we reflect on five years of COVID-19, it’s clear that the impacts are still unfolding. The life sciences—and we as individuals—will never be the same again.

March 11, 2025

6 min read

Jef Akst